학술논문

Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality?
Document Type
Article
Source
Ocular Immunology & Inflammation. Oct/Nov2022, Vol. 30 Issue 7/8, p1763-1767. 5p.
Subject
*JUVENILE idiopathic arthritis
*IRIDOCYCLITIS
*UVEITIS
*METHOTREXATE
*DISEASE remission
*BIOLOGICALS
Language
ISSN
0927-3948
Abstract
To evaluate the long-term efficacy of methotrexate (MTX) monotherapy in patients with juvenile idiopathic arthritis-associated uveitis (JIA-U). We analyzed a cohort of patients with JIA-U treated with MTX monotherapy, divided into two groups depending on whether MTX was started before (on-MTX group) or after uveitis diagnosis (MTX-naïve group). The primary endpoint was the time between uveitis inactivity and first relapse. 84 patients entered the study. The median duration of remission on MTX monotherapy resulted 8.2 months. The on-MTX group showed a significant longer time interval between arthritis and uveitis onset and higher need for biologic agents (bDMARD). During follow-up, 40 patients (47.6%) needed bDMARD due to poor control of uveitis. Clinical remission off medication was achieved in 11.9% of patients, all belonging to the MTX-naïve group. MTX monotherapy, although effective in early stages of JIA-U, showed poor disease control in the long term. [ABSTRACT FROM AUTHOR]